References
- Roumen FJME, Mishell DR. The contraceptive vaginal ring, NuvaRing®, a decade after its introduction. Eur J Contracept Reprod Health Care. 2012;17:415–427.
- Gaussem P, Alhenc-Gelas M, Thomas J-L, et al. Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17beta-estradiol, compared with those of levonorgestrel/ethinyl estradiol: a double-blind, randomized study. Thromb Haemost. 2011;105:560–567.
- Ågren UM, Anttila M, Maenpaa-Liukko K, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17beta-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur J Contracept Reprod Health Care. 2011;16:444–457.
- Junge W, Mellinger U, Parke S, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31:573–584.
- Miettinen OS, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213–226.
- Insler V, Melmed H, Eichenbrenner I, et al. The cervical score. A simple semiquantitative method for monitoring the menstrual cycle. Int J Gynaecol Obstet. 1972;10:223–228.
- Milsom I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing®, versus an oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone. Hum Reprod. 2006;21:2304–2311.
- Oddsson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 µg ethinylestradiol and 150 µg levonorgestrel: a randomized trial. Hum Reprod. 2005;20:557–562.
- Mansour D, Verhoeven C, Sommer W, et al. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011;16:430–443.
- Ahrendt H-J, Makalová D, Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80:436–444.
- Apter D, Zimmerman Y, Beekman L, et al. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA) ). Contraception. 2016;94:366–373.
- Lin K-C, Sun M-J. Relationship between sex hormone-binding globulin and pregnancy outcome in women undergoing controlled ovarian hyperstimulation for assisted reproduction. Endocr J. 2005;52:407–412.
- Gerrits MGF, Schnabel PG, Post TM, et al. Pharmacokinetic profile of nomegestrol acetate and 17beta-estradiol after multiple and single dosing in healthy women. Contraception. 2013;87:193–200.
- Stanczyk FZ, Archer DF, Bhavnani BR. Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment. Contraception. 2013;87:706–727.
- Lobo R, Cassidenti DL. Pharmacokinetics of Oral 17β-Estradiol. J Reprod Med. 1992;37:67–84.
- Pasqualini J, Chetrite G, Blacker C, et al. Concentration of estrone, estradiol, and estrone-sulfate in and evaluation of sulfatase and aromatase activity in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab.1996;81:1460–1464.
- Odlind V, Milsom I, Persson I, et al. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? A discussion based on recent recommendations from the European agency for evaluation of medicinal products regarding third generation oral contraceptive pills. Acta Obstet Gynecol Scand. 2002; 81:482–490.